ArticleFrontiers in oncology2025
LungPanelNet: a machine learning-based approach for the early prediction and differentiation of non-small cell lung cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) represents a major global health challenge, primarily due to its frequent diagnosis at advanced stages, which significantly limits therapeutic efficacy and results in poor survival outcomes. A critical unmet need exists for non-invasive, accurate diagnostic tools for early detection.
objectiveThis study aimed to develop and validate a robust machine learning model based on a panel of serum tumor markers for the early prediction of NSCLC and its differentiation from benign pulmonary conditions.
methodsIn this retrospective cohort study, we recruited 2,283 participants, including 1,339 with NSCLC, 313 with pneumonia, 260 with biopsy-confirmed benign lesions, and 371 with other benign lung masses. Serum levels of six key tumor markers-Squamous Cell Carcinoma Antigen (SCCA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA-125), Cytokeratin 19 Fragment (CYFRA21-1), Neuron-Specific Enolase (NSE), and Pro-Gastrin-Releasing Peptide (ProGRP)-were quantified, and a custom deep neural network, LungPanelNet, was constructed for the classification task.
resultsThe model demonstrated superior predictive performance on an independent testing set, achieving an area under the receiver operating characteristic curve (AUC-ROC) of 0.92 (95% CI: 0.88-0.96), with an accuracy of 89.3%, a sensitivity of 91.5%, and a specificity of 87.8%. Feature importance analysis identified SCCA and CYFRA21-1 as the most significant predictors.
conclusionOur findings demonstrate that a machine learning model integrating a panel of serum tumor markers can effectively distinguish NSCLC from a spectrum of benign pulmonary conditions with high accuracy. This approach shows promise as a clinical decision-support tool, though further validation in larger, prospective, multi-center cohorts is warranted. This was a retrospective cohort study without clinical trial registration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.